Radiation oncology company Accuray has partnered with Germany-based Brainlab to enhance and expand the capabilities of its CyberKnife platform for the neuro-radiosurgery market.
CyberKnife is a robotic, non-invasive radiation therapy device used for the treatment of cancerous and benign tumours throughout the body. It is also intended for the treatment of functional neurologic disorders.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Additionally, the platform is also used to treat conditions in the brain while reducing the dose to brain tissues, which play a vital role in functions such as hearing and vision.
The system has robotic architecture and fully integrated image guidance, continual delivery adaptation, and motion synchronisation. It supports the delivery of stereotactic radiosurgery with sub-millimetre precision and accuracy.
As part of the agreement, the companies will work together to offer access to Brainlab Elements planning software to the neuro-radiosurgery community.
The software is designed to deliver optimised contouring capabilities for neurosurgeons.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn addition, the companies plan to leverage interoperability with Brainlab health-tech platform Snke OS, which improves the experience for people administering and receiving radiation treatments.
Snke OS platform forms a link between data sources, driving useful insights and analytics.
The move will enable customers to add CyberKnife treatment data through Brainlab’s patient registry platform Quentry. It will help them to participate in the neuro-radiosurgery patient registries to facilitate improved patient outcomes.
Accuray CEO and president Joshua Levine said: “The Accuray team is excited to partner with Brainlab, recognised leaders in treatment planning, surgical navigation and innovators in radiotherapy and radiosurgery solutions that advance patient care.
“This marks an important next step in the evolution of the CyberKnife platform by expanding the capabilities to align with the needs of the neurosurgical community. We believe our two companies bring powerful and complementary expertise that, when combined, will raise the bar for what can be achieved in terms of efficiency, accuracy, and precision on behalf of neurosurgeons and their patients.”
Accuray launched the CyberKnife S7 System in June.
